Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy.
about
Non-immunosuppressive treatment for IgA nephropathyExpression patterns of podocyte-associated mRNAs in patients with proliferative or non-proliferative glomerulopathiesEfficacy and safety of adding mizoribine to standard treatment in patients with immunoglobulin A nephropathy: A randomized controlled trialAdvances in the pathophysiology of pre-eclampsia and related podocyte injury.Podocyte number in the maturing rat kidneyReduced glomerular epithelial protein 1 expression and podocyte injury in immunoglobulin A nephropathy.Mesangial cell proliferation inhibitors for the treatment of proliferative glomerular disease.Urinary excretion of viable podocytes in health and renal disease.Research into the glomerular podocyte--is it relevant to diabetic nephropathy?Glomerular epithelial cells in the urine: what has to be done to make them worthwhile?Relationship between urinary podocytes and kidney diseases.Dipping your feet in the water: podocytes in urine.B7-1 expression regulates the hypoxia-driven cytoskeleton rearrangement in glomerular podocytes.Urinary and glomerular podocytes in patients with chronic kidney diseases.Recent Progress in the Pathogenesis of Nephrotic ProteinuriaACE insertion/deletion polymorphism (rs1799752) modifies the renoprotective effect of renin-angiotensin system blockade in patients with IgA nephropathy
P2860
Q24235956-FAEECB93-ED14-4009-AA19-6F1083D41CD2Q33803050-DED4D84C-9401-4149-AAC5-EB4612FE5210Q33853495-E1C80953-2E66-4E93-91A6-6B0F1FBF4453Q33983807-8895565D-E206-4D2F-A2AD-CFA47F61FD1AQ34537769-DFC0B155-864D-42DB-B58F-6409C1937945Q34642039-489056A3-46C7-4293-9792-24608B12F6E5Q34993147-2E1942DE-AAA1-42FD-B4EA-42A6B742A2E9Q36012253-99FFCACE-ADF4-4A51-9880-A873F4502EC2Q36536737-9CF8AC80-62FB-4EFA-8FF3-E9B39DBA53C4Q37289620-A0175D46-14BA-4E0B-A5CE-9CCC35440CE6Q37976448-321592AC-3082-49D2-B98C-C761EC481F96Q38203904-23AE6DC2-CAA1-45FD-8923-2522689C3C2CQ39270044-5A99B3EC-E3CF-4CB5-B5FD-D72E021DE419Q45730002-4C844AEC-2E91-4734-98A2-A2156E846491Q57825276-996C8D70-8030-4BCF-8D0B-0261A96C7E3AQ58362610-F12BCE79-508B-4C12-BDC6-683650745900
P2860
Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Effects of angiotensin-convert ...... patients with IgA nephropathy.
@en
Effects of angiotensin-convert ...... patients with IgA nephropathy.
@nl
type
label
Effects of angiotensin-convert ...... patients with IgA nephropathy.
@en
Effects of angiotensin-convert ...... patients with IgA nephropathy.
@nl
prefLabel
Effects of angiotensin-convert ...... patients with IgA nephropathy.
@en
Effects of angiotensin-convert ...... patients with IgA nephropathy.
@nl
P2093
P356
P1476
Effects of angiotensin-convert ...... patients with IgA nephropathy.
@en
P2093
C Ushiyama
K Sekizuka
T Nakamura
P304
P356
10.1159/000013619
P577
2000-09-01T00:00:00Z